Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Hindustan Bio Sciences's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹-4.52 Mil. Hindustan Bio Sciences's average total tangible assets for the quarter that ended in Jun. 2026 was ₹31.95 Mil. Therefore, Hindustan Bio Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -14.13%.
The historical rank and industry rank for Hindustan Bio Sciences's Return-on-Tangible-Asset or its related term are showing as below:
BOM:532041'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -47.5 Med: -1.84 Max: 2.97
Current: -6.11
During the past 13 years, Hindustan Bio Sciences's highest Return-on-Tangible-Asset was 2.97%. The lowest was -47.50%. And the median was -1.84%.
BOM:532041's Return-on-Tangible-Asset is ranked worse than 72.72% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.795
vs BOM:532041: -6.11
Hindustan Bio Sciences (BOM:532041) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Hindustan Bio Sciences Return-on-Tangible-Asset Related Terms
Hindustan Bio Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Hindustan Bio Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hindustan Bio Sciences Return-on-Tangible-Asset Chart
BOM:532041 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hindustan Bio Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hindustan Bio Sciences Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hindustan Bio Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Hindustan Bio Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -14.13% mean?
Hindustan Bio Sciences (BOM:532041) has a Return-on-Tangible-Asset of -14.13% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hindustan Bio Sciences and its competitors. According to the industry distribution chart, Hindustan Bio Sciences ranks #733 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 72.7%.
Is Hindustan Bio Sciences' Return-on-Tangible-Asset too high?
Hindustan Bio Sciences' current Return-on-Tangible-Asset is -14.13%. Based on the distribution chart, Hindustan Bio Sciences ranks #733 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hindustan Bio Sciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hindustan Bio Sciences' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hindustan Bio Sciences ranks #733 out of 1008 companies for Return-on-Tangible-Asset. This places Hindustan Bio Sciences in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.80, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hindustan Bio Sciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hindustan Bio Sciences's current Return-on-Tangible-Asset is -14.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hindustan Bio Sciences stock overvalued right now?
Based on GuruFocus' analysis, Hindustan Bio Sciences (BOM:532041) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹3.13, compared to a current price of ₹7.45 — trading 138% above its estimated fair value. The current Return-on-Tangible-Asset is -14.13%. Hindustan Bio Sciences' overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Hindustan Bio Sciences (BOM:532041), the current Return-on-Tangible-Asset is -14.13% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hindustan Bio Sciences (BOM:532041) Overvalued in 2026?
Based on GuruFocus' analysis, Hindustan Bio Sciences stock appears to be overvalued.
The current stock price of ₹7.45 is trading 138% above its estimated GF Value™ of ₹3.13.
GuruFocus considers Hindustan Bio Sciences to be Significantly Overvalued.
Key valuation signals for BOM:532041:
Return-on-Tangible-Asset: -14.13%
GF Value™: ₹3.13 vs. price of ₹7.45 (138% above fair value)
No single metric tells the full story. See the BOM:532041 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hindustan Bio Sciences Ltd is an Indian pharmaceutical company, engaged in the manufacturing and sale of pharmaceutical products. The company manufactures and markets drugs and medicines in tablets, capsules, drops, externels, and syrup forms. Geographically, all of its revenue is generated through the export of its products to international markets.
41GF Score
Get the complete analysis for BOM:532041
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532041 has been successfully added to your 
